Vimarsana
Biggest News Aggregation in the World

Cutan Med News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cutan Med. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cutan Med Today - Breaking & Trending Today

LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences - Vimarsana News

LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences

MADISON, N.J.--(BUSINESS WIRE)--Jan 12, 2024--

Stigmatizing Attitudes Against Individuals with Acne Observed in Several Different Settings - Vimarsana News

Stigmatizing Attitudes Against Individuals with Acne Observed in Several Different Settings

Given the lack of widespread awareness of the magnitude and prevalence of the public’s stigma toward people with acne, this research sought to expand upon this body of research.

LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023 - Vimarsana News

LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023

BALLERUP, Denmark, October 13, 2023--LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023

Source: yahoo.com
Biologics Efficacy, Safety Not Significantly Impacted by Comorbidities in Older Adults with Psoriasis - Vimarsana News

Biologics Efficacy, Safety Not Significantly Impacted by Comorbidities in Older Adults with Psoriasis

New data indicates that biologic treatments for psoriasis patients were found not to be significantly affected by comorbidities in older patients, widening the understanding of biologic use in different subgroups.

Roflumilast Foam Efficacious, Safe in Treating Seborrheic Dermatitis Symptoms - Vimarsana News

Roflumilast Foam Efficacious, Safe in Treating Seborrheic Dermatitis Symptoms

New data indicate that once-daily roflumilast foam in treating seborrheic dermatitis may improve the lives of those in the 5% or more of the global population with the skin disease.